STOCK TITAN

PAVmed Q3 2026 net loss widens to $11.7M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

PAVmed Inc. reported preliminary third-quarter 2026 revenue of $41,000, compared with $5,000 a year earlier. Its net loss as reported was $11.655 million, versus $5.383 million, while non-GAAP adjusted loss was $1.240 million, versus $446,000. For the nine months ended September 30, 2026, revenue was $96,000 versus $19,000; net loss as reported was $17.099 million versus net income of $1.664 million, and non-GAAP adjusted loss was $4.759 million versus $2.199 million.

Lucid Diagnostics' EsoGuard is now fully reimbursed by Medicare nationwide. Veris Health completed a design freeze for its implantable physiological monitor and began a 90-day GLP animal study ahead of an early 2027 FDA submission. PAVmed said it is engaged with FDA on PortIO and Octeris. Octeris completed its next-generation multimodal endoscopic imaging probe, which is ready for clinical testing; it expects to submit its initial FDA pre-submission package this month, and enrollment in a University of North Carolina clinical validation study is expected to begin in January 2027.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 2 points

How the balance works

Positive

  • Minor pointThird-quarter revenue was $41,000, versus $5,000 in 2025.

Negative

  • Major pointReported third-quarter net loss was $11.655 million, versus $5.383 million in 2025.
  • Minor pointNon-GAAP adjusted third-quarter loss was $1.240 million, versus $446,000 in 2025.
Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Third-quarter revenue $41,000 Three months ended September 30, 2026; $5,000 in 2025
Nine-month revenue $96,000 Nine months ended September 30, 2026; $19,000 in 2025
Third-quarter net loss as reported ($11.655 million) Three months ended September 30, 2026; loss of $5.383 million in 2025
Third-quarter non-GAAP adjusted loss ($1.240 million) Three months ended September 30, 2026; loss of $446,000 in 2025
Third-quarter non-GAAP adjusted loss per share ($0.19) per share Three months ended September 30, 2026; ($0.62) per share in 2025
Nine-month net loss as reported ($17.099 million) Nine months ended September 30, 2026; net income of $1.664 million in 2025
Nine-month non-GAAP adjusted loss ($4.759 million) Nine months ended September 30, 2026; loss of $2.199 million in 2025
Veris GLP animal study duration 90 days Study initiated for the implantable physiological monitor
GLP animal study medical
"initiated 90-day GLP animal study"
implantable physiological monitor medical
"advancing its implantable physiological monitor"
FDA pre-submission package regulatory
"submit its initial FDA pre-submission package"
EBITDA financial
"EBITDA"
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It measures a company's profitability by focusing on the money it makes from its core operations, ignoring expenses like taxes and accounting adjustments. Investors use EBITDA to compare how well different companies are performing financially, as it provides a clearer picture of operational success without the influence of financial structure or accounting choices.
equity method investments financial
"Change in FV equity method investments"
An equity method investment is an accounting approach used when a company owns a significant share of another company and can influence its decisions but does not fully control it; instead of listing the investment at cost, the investor records its share of the other company's profits or losses on its own income statement and adjusts the investment value on the balance sheet. For investors, this matters because it links the investor’s reported earnings and asset values directly to the financial performance of that partly-owned business, similar to how a partner’s gains affect a small business owner’s books.
stock-based compensation financial
"Stock-based compensation expense"
Stock-based compensation is when a company pays employees, directors or consultants with shares or the right to buy shares instead of or in addition to cash. It matters to investors because issuing stock or options spreads ownership thinner (like cutting a pie into more slices), which can reduce each existing share’s claim on profits and can also change reported earnings; investors watch it to assess true cost of running the business and how management is incentivized.
Revenue, third quarter $41,000 Versus $5,000 in 2025
Net income (loss) as reported, third quarter ($11.655 million) Versus a loss of $5.383 million in 2025
Non-GAAP adjusted loss, third quarter ($1.240 million) Versus ($446,000) in 2025
Non-GAAP adjusted loss per share, third quarter ($0.19) per share Versus ($0.62) per share in 2025
Revenue, nine months $96,000 Versus $19,000 in 2025
Net income (loss) as reported, nine months ($17.099 million) Versus net income of $1.664 million in 2025
Non-GAAP adjusted loss, nine months ($4.759 million) Versus ($2.199 million) in 2025
Non-GAAP adjusted loss per share, nine months ($0.98) per share Versus ($3.69) per share in 2025

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were PAVM's third-quarter 2026 revenue and losses?

PAVmed reported preliminary revenue of $41,000 for the three months ended September 30, 2026, compared with $5,000 in 2025. Net loss as reported was $11.655 million, versus $5.383 million, and non-GAAP adjusted loss was $1.240 million, versus $446,000.

What were PAVM's financial results for the first nine months of 2026?

For the nine months ended September 30, 2026, revenue was $96,000, compared with $19,000 in 2025. Net loss as reported was $17.099 million, compared with net income of $1.664 million, and non-GAAP adjusted loss was $4.759 million, versus $2.199 million.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001624326 0001624326 2026-11-13 2026-11-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): November 13, 2026

 

PAVMED INC.

 

(Exact Name of Registrant as Specified in Charter)

 

Delaware   001-37685   47-1214177
(State or Other Jurisdiction
of Incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

360 Madison Avenue, 25th Floor, New York, New York   10017
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (917) 813-1828

 

N/A
(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, Par Value $0.001 Per Share   PAVM   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On November 13, 2026, PAVmed Inc. (the “Company”) issued a press release announcing financial results for its fiscal quarter ended September 30, 2026 and providing a business update. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated herein by reference.

 

Item 7.01. Regulation FD Disclosure.

 

The disclosure set forth under Item 2.02 is incorporated herein by reference.

 

The information furnished under Items 2.02 and 7.01, including the exhibit related thereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any disclosure document of the Company, except as shall be expressly set forth by specific reference in such document.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits:

 

Exhibit No.   Description
99.1   Press release.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: November 13, 2026 PAVMED INC.
   
  By: /s/ Dennis McGrath
    Dennis McGrath
    President and Chief Financial Officer

 

 

 

 

Exhibit 99.1

 

PAVmed Provides Business Update and Reports Preliminary Third Quarter 2026 Financial Results

 

Lucid Diagnostics’ EsoGuard® now fully reimbursed by Medicare nationwide

 

Veris Health achieved implantable physiological monitor design freeze and initiated 90-day GLP animal study ahead of early 2027 FDA submission

 

PAVmed engaged with FDA on PortIO and Octeris

 

Conference call and webcast to be held today, November 13, at 8:30 AM EST

 

NEW YORK, November 13, 2026 - PAVmed Inc. (NASDAQ: PAVM) (“PAVmed” or the “Company”), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) (“Lucid”), Veris Health Inc. (“Veris”), and Octeris Medical Inc. (“Octeris”), and reported financial results for the third quarter ended September 30, 2026.

 

Conference Call and Webcast

 

The webcast will take place on Friday, November 13, 2026, at 8:30 AM EST and is accessible in the investor relations section of the Company’s website at pavmed.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name “PAVmed Business Update” to join.

 

Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company’s website at pavmed.com.

 

Business Update Highlights

 

“We’re very encouraged by developments across the PAVmed portfolio,” said Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer. “Lucid securing Medicare reimbursement for EsoGuard is a critical and transformational milestone. As Lucid’s largest common shareholder, PAVmed stands to benefit directly from Lucid’s substantial near-term revenue opportunity. Veris continues to grow enrollment at Ohio State while advancing its implantable monitor toward FDA submission. We are also now actively engaged with FDA on both PortIO and Octeris. We believe this progress puts PAVmed in a strong position to create real long-term shareholder value.”

 

 

 

 

Highlights from the third quarter and recent weeks:

 

●Lucid Diagnostics:

 

◌Began receiving payments from Medicare for the EsoGuard® Esophageal DNA Test in October. Lucid is submitting Medicare claims for tests performed at its Texas laboratory to Novitas, the Medicare Administrative Contractor (MAC) with jurisdiction over that laboratory, and is receiving payments at EsoGuard’s established Clinical Laboratory Fee Schedule rate.

 

◌Focused commercial efforts on expanding EsoGuard access among at-risk Medicare beneficiaries, who represent approximately 50% of the 30 million patients recommended for esophageal precancer testing by professional society guidelines.

 

◌Announced publication of an 11,991-patient real-world EsoGuard study in the peer-reviewed journal Diagnostics, the largest peer-reviewed study of nonendoscopic esophageal precancer testing to date, demonstrating the efficiency and scalability of the EsoCheck® Esophageal Cell Collection Device.

 

◌Performed 2,871 EsoGuard tests and recognized revenue of $1.2 million in 3Q26. October was a record month for EsoGuard test volume, with more than 1,800 tests.

 

●Veris Health:

 

◌Monthly patient enrollment at OSU-The James grew throughout the quarter, nearly doubling from July to September, as the commercial phase of the strategic engagement continued to accelerate and the clinical rollout went live across most departments.

 

◌Achieved design freeze for the implantable physiological monitor and, in October, initiated the 90-day GLP animal study, keeping the device on track for an early 2027 FDA 510(k) submission.

 

●PortIO:

 

◌Held an initial meeting with FDA on PortIO in late October, to be followed by an in-person pre-submission meeting in January 2027 focused on the device’s regulatory pathway.

 

●Octeris:
  
◌Completed Octeris’ next-generation multimodal endoscopic imaging probe, which is ready for clinical testing. Octeris expects to submit its initial FDA pre-submission package this month, with enrollment in the University of North Carolina clinical validation study expected to begin in January 2027.

 

 

 

 

Preliminary Financial Results:

 

●For the three months ended September 30, 2026, operating expenses were approximately $6.8 million, which included stock-based compensation expenses of $1.0 million.

 

●As shown below and for the purpose of illustrating the effect of stock-based compensation and other non-cash income and expenses on the Company’s financial results, the Company’s non-GAAP adjusted net loss was approximately $1.2 million or $(0.19) per common share.

 

●PAVmed had cash and cash equivalents of $8.9 million, including restricted cash of $5.3 million, as of September 30, 2026, compared to cash and cash equivalents of $1.5 million, including $0.3 million of restricted cash, as of December 31, 2025.

 

PAVmed Non-GAAP Measures

 

●To supplement our financial results presented in accordance with U.S. generally accepted accounting principles (GAAP), management provides certain non-GAAP financial measures of the Company’s financial results. These non-GAAP financial measures include net loss before interest, taxes, depreciation, and amortization (EBITDA) and non-GAAP adjusted loss, which further adjusts EBITDA for stock-based compensation expense, loss on the issuance or modification of convertible securities, the periodic change in fair value of convertible securities, and loss on debt extinguishment. The foregoing non-GAAP financial measures of EBITDA and non-GAAP adjusted loss are not recognized terms under U.S. GAAP.

 

●Non-GAAP financial measures are presented with the intent of providing greater transparency to the information used by us in our financial performance analysis and operational decision-making. We believe these non-GAAP financial measures provide meaningful information to assist investors, shareholders, and other readers of our financial statements in making comparisons to our historical financial results and analyzing the underlying performance of our results of operations. These non-GAAP financial measures are not intended to be, and should not be, a substitute for, considered superior to, considered separately from, or as an alternative to, the most directly comparable GAAP financial measures.

 

●Non-GAAP financial measures are provided to enhance readers’ overall understanding of our current financial results and to provide further information for comparative purposes. Management believes the non-GAAP financial measures provide useful information to management and investors by isolating certain expenses, gains, and losses that may not be indicative of our core operating results and business outlook. Specifically, the non-GAAP financial measures include non-GAAP adjusted loss, and its presentation is intended to help the reader understand the effect of the loss on the issuance or modification of convertible securities, the periodic change in fair value of convertible securities, the loss on debt extinguishment and the corresponding accounting for non-cash charges on financial performance. In addition, management believes non-GAAP financial measures enhance the comparability of results against prior periods.

 

 

 

 

●A reconciliation to the most directly comparable GAAP measure of all non-GAAP financial measures included in this press release for the three and nine months ended September 30, 2026 and 2025 are as follows:

 

  For the three months ended
September 30,
  For the nine months ended
September 30,
   2026  2025  2026  2025
(in thousands except per-share amounts)            
Revenue  $41   $5   $96   $19 
Operating expenses   6,768    4,849    21,879    15,022 
Other (Income) Expense, net   6,308    1,167    (1,087)   (15,291)
Net (Income) Loss   13,035    6,011    20,696    (288)
Net income (loss) attributable to common stockholders   (11,752)   (6,328)   (24,219)   (1,942)
Preferred Stock dividends and deemed dividends   97    945    7,120    3,606 
Net income (loss) as reported   (11,655)   (5,383)   (17,099)   1,664 
Adjustments:                    
Depreciation and amortization expense1   19    22    58    87 
Interest expense, net2   (2)   (2)   (26)   (8)
NCI ownership share of Interest and Depreciation adjustments   (268)   —    (775)   — 
EBITDA   (11,906)   (5,363)   (17,842)   1,743 
                     
Other non-cash or financing related expenses:                    
Stock-based compensation expense3   967    383    2,065    1,475 
Operating expenses issued in stock1   140    52    2,091    155 
Change in FV equity method investments   9,985    4,382    10,612    (5,979)
Preliminary Change in FV convertible debt2   (330)   100    (3,126)   349 
Loss on debt extinguishment2   —     —    3,422    58 
Change in fair value – warrant liability   —     —    (1,831)   — 
Change in fair value – rights liability   (96)   —    (150)   — 
Non-GAAP adjusted (loss)  $(1,240)  $(446)  $(4,759)  $(2,199)
Non-GAAP shares outstanding, basic and diluted   6,640    718    4,849    596 
Non-GAAP adjusted (loss) income per share, basic and diluted  $(0.19)  $(0.62)  $(0.98)  $(3.69)

 

1 Included in general and administrative expenses in the financial statements.

 

2 Included in other income and expenses.

 

 

 

 

3 Stock-based compensation (“SBC”) expense is included in operating expenses and is detailed as follows in the table below by category within operating expenses for the non-GAAP Net operating expenses:

 

(in thousands except per-share amounts) 

For the three months ended

September 30,

  For the nine months ended
September 30,
   2026  2025  2026  2025
             
Cost of revenue  $158   $55   $377   $133 
Stock-based compensation expense3   —      —      —      —   
Net cost of revenue   158    55    377    133 
                     
Sales and marketing   206    201    636    668 
Stock-based compensation expense3   (17)   (13)   (30)   (59)
Net sales and marketing   189    188    606    609 
                     
General and administrative   4,482    3,505    15,489    11,557 
Depreciation expense   (19)   (22)   (58)   (87)
Operating expenses issued in stock   (140)   (52)   (2,091)   (155)
Stock-based compensation expense3   (899)   (332)   (1,927)   (1,276)
Net general and administrative   3,424    3,099    11,413    10,039 
                     
Research and development   1,922    1,088    5,377    2,664 
Stock-based compensation expense3   (51)   (38)   (108)   (140)
Net research and development   1,871    1,050    5,269    2,524 
                     
Total operating expenses   6,768    4,849    21,879    15,022 
Depreciation and amortization expense   (19)   (22)   (58)   (87)
Operating expenses issued in stock   (140)   (52)   (2,091)   (155)
Stock-based compensation expense3   (967)   (383)   (2,065)   (1,475)
Net operating expenses  $5,642   $4,392   $17,665   $13,305 

 

 

 

 

About PAVmed and its Subsidiaries

 

PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its subsidiary, Lucid Diagnostics Inc. (NASDAQ: LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices. Veris is concurrently developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the Veris Cancer Care Platform.

 

For more information about PAVmed, please visit pavmed.com.

 

For more information about Lucid Diagnostics, please visit luciddx.com.

 

For more information about Veris Health, please visit verishealth.com.

 

Forward-Looking Statements

 

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of PAVmed’s and Lucid’s management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed’s and Lucid’s common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance PAVmed’s and Lucid’s products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed’s and Lucid’s clinical and preclinical studies; whether and when PAVmed’s and Lucid’s products are cleared by regulatory authorities; market acceptance of PAVmed’s and Lucid’s products once cleared and commercialized; PAVmed’s and Lucid’s ability to raise additional funding as needed; and other competitive developments. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect PAVmed’s and Lucid’s future operations, see Part I, Item 1A, “Risk Factors,” in PAVmed’s and Lucid’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, “Risk Factors” in any Quarterly Report on Form 10-Q filed by PAVmed or Lucid after its most recent Annual Report. PAVmed and Lucid disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

 

Investor and Media Contact

 

Matt Riley

Vice President
PAVmed and Lucid Diagnostics
mjr@pavmed.com

 

 

Filing Exhibits & Attachments

4 documents

Keep reading